Search results | Monoclonal antibodies

Reports

Monoclonal Antibodies Partnering Terms and Agreements

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals.

Antibody Partnering Terms & Agreements

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Seattle Genetics: Empowering monoclonal antibodies

Seattle Genetics is a biotech company developing and commercializing antibody-based therapeutics to improve the lives of people living with cancer.

Monoclonal antibodies

Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made…

PDL Biopharma: Capitalizing on the humanization of monoclonal antibodies

PDL Biopharma based in Nevada manages patents associated with its humanized monoclonal antibodies technology.   

Industry analysis: Cancer monoclonal antibody partnering on the rise

Monoclonal antibodies are developed to be very selective in targeting cells. This is why they have come to be an indispensable research tool in cancer treatment being able to specifically target tumor cells.

Market research analysis: Monoclonal antibody partnering

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years

Polyclonal antibodies

Polyclonal antibodies (or antisera) are antibodies that are obtained from different B cell resources

Current deal trends and prospects in therapeutic antibodies

As a therapeutic, monoclonal antibodies are coming of age in that innovative companies have been persistent in improving upon an already effective therapeutic development strategy

Q2 Partnering and Licensing Pharma trends of 2014

July 2014 By Raveena Bhambra Q2 was full of deals, coupled with the talk of potential deals, and overall it finished on a high with a large volume of agreements coming together in June.

Antibody: recent life science partnering trends

Antibodies are the subject of numerous partnering deals every year, here we provide a review of recent partnering trends activity.

Antibody-drug conjugates

Antibody-drug conjugates (ADCs) are a new type of targeted therapy, used for example for cancer

Events

Sorry, your search returned no results.


Deals

Licensing agreement for monoclonal antibodies

Visterra has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus.

Vivalis partners with Sanofi Pasteur for the discovery of human monoclonal antibodies against infectious diseases

Vivalis has announced the signature with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, of a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious disease targets.

Pfizer biotech deals Harbour Antibodies for H2L2 mice

Harbour Antibodies has licensed its H2L2 mice, which can generate human monoclonal antibodies, to Pfizer in biotech deals.

Merck big pharma deals Xencor for monoclonal antibody licensing agreement

Xencor enters pharma deals with Merck for the licensing of Xencor’s Fc engineering patents for a therapeutic monoclonal antibody to the big pharma company.

Pfizer signs a pharma licensing deal with Open Monoclonal Technology

Pfizer, the world’s largest pharmaceutical company collaborated with Open Monoclonal Technology by signing a  pharma licensing agreement with the latter to use OMT’s OmniRat for antibody research and development

Therapeutic antibodies research attract pharma partnering pact between Pfizer & Visterra

The world’s largest pharmaceutical company Pfizer, has inked a pharma partnering pact with Visterr to focus on the discovery of therapeutic antibodies based on the latter’s platform for the identification of drug target sites and drug design

Amorfix licenses ALS antibodies to Biogen Idec

Amorfix Life Sciences Ltd. has announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix’s lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies.

Oxford BioTherapeutics and GlaxoSmithKline form alliance to develop novel cancer therapeutic antibodies

GSK will develop novel antibody therapies against selected OBT targets. In parallel OBT will develop one of its own monoclonal antibodies through to clinical proof of concept, at which point GSK will have an exclusive option to in-license this monoclonal antibody and will thereafter assume responsibility for further clinical development and commercialisation on a worldwide more »

Series B financing for $90 million for Kymab

Kymab has successfully raised an additional US$50 million to complete a US$90 million Series B financing.

Sanofi and Boehringer Ingelheim in antibody manufacturing pact

Boehringer Ingelheim and Sanofi enter into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies